Author Archives: Pharm Exec

Viehbacher Exits Sanofi

Christopher A. Viehbacher resigned as director of Sanofi immediately after its Board of Directors unanimously agreed to remove him as the company’s CEO yesterday. Chairman Serge Weinberg will replace Viehbacher on an interim basis.
Posted in Europe, Global, leadership, Strategy | Tagged , | Leave a comment

NHL Treatment Market Boom Will Be Hindered in EU

The global non-hodgkin lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, according to GBI Research.
Posted in Europe, R&D, Strategy | Tagged , , , , , , | Leave a comment

Gilead and Yale Extend Sequencing Initiative

After having already sequenced thousands of cancer genes in projects together, the Yale School of Medicine and Gilead announced they will continue their partnership to find therapeutic candidates for cancer for an additional three years. The original agreement was forged in 2011 and can be renewed for up to 10 years.
Posted in R&D, Strategy, Technology | Tagged , | Leave a comment

Pharma Feels Impact of US Tax Inversion Legislation

The recent termination of AbbVie’s deal to acquire Shire has “jolted the industry out of its reverie” by becoming pharma’s first major casualty of new US tax inversion legislation,  says research and consulting firm GlobalData.
Posted in Deals, Europe, Global, Strategy | Tagged , , , | Leave a comment

US Healthcare Reform: A Pharm Exec Digest Special

This month’s special issue of Pharm Exec Global Digest looks at Dealing with the “side effects” of Obamacare The “value” of Rxs under Obamacare The escalating cost of US oncology care And more… Click here to read the issue.
Posted in Global, healthcare, Regulatory | Tagged , , , | Leave a comment
  • Categories

  • Meta